

DAFTAR PUSTAKA

Arends MJ., Buckley CH., Wells M.. Aetiology, pathogenesis, and pathology of cervical neoplasia. *J Clin Pathol* 1998;51:96-103.

ATCC. 2014. MTT Cell Proliferation Assay.

Bernard HU., Burk RD., Chen Z., et al. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. *Virology*. 2010;401(1):70–79.

Bosch FX., Burchell AN., Schiffman M., et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. *Vaccine*. 2008;26(suppl 10):K1–K16.

Bouvard V., Baan R., Straif K., et al. A review of human carcinogens—part B: biological agents. *Lancet Oncol*. 2009;10(4):321–322.

Castle PE., Solomon D., Schiffman M., Wheeler CM.. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. *J Natl Cancer Inst*. 2005;97(14):1066–1071.

Centers for Disease Control and Prevention. 2012. *Cervical Cancer Statistic*, (Online), (<http://www.cdc.gov/cancer/cervical/statistics/>, diakses 20 Oktober 2015).

Cohen S., Graham M., Lovrecz G., Bache N., Robinson P., Reddel R.. Protein composition of catalytically active human telomerase from immortal cells. *Science*. 2007; 315 (5820): 1850–3doi:10.1126/science.1138596. PMID 17395830.

Dharmacon. 2014. Basic siRNA Resuspension.

Dharmacon. 2014. DharmaFECT™ Transfection Reagents.

Doorbar J.. Papillomavirus life cycle organization and biomarker selection. *Dis Markers*. 2007;23(4):297–313.

Fakhry C., Gillison ML.. Clinical implications of human papillomavirus in head and neck cancers. *J Clin Oncol*. 2006;24(17):2606–2611.

Hanafiah. 2005. Statistik Kedokteran. Jakarta: Bumi Cipta.

Hong, Lu, Ye, Wu, Xie. Gene silencing of HPV16 E6/E7 induced by promoter-targeting siRNA in SiHa cells. *British Journal of Cancer*. 2009;101: 1798 – 1804.

ICO Information Centre on HPV and Cancer. 2014. *Human Papillomavirus and Related Diseases Report*. Barcelona: Institut Català d'Oncologia.

Li N., Franceschi S., Howell-Jones R., Snijders PJ., Clifford GM.. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. *Int J Cancer*. 2011;128(4):927–935.

McCredie MR., Sharples KJ., Paul C., et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. *Lancet Oncol*. 2008;9(5):425–434.

Morandell, Dieter., et al. 2012. *The Human Papilloma Virus Type 16 E7 Oncoprotein Targets Myc-Interacting Zinc-Finger Protein-1*. *Virology*(422(2)) : 242-253.

Morrison, Morreale, Akunuru, et al. Targeting the Human Papillomavirus E6 and E7 oncogenes through expression of the BPV1 E2 protein stimulates cellular motility. *J. Virol*. doi:10.1128/JVI.05126-11.

Munoz N., Hernandez-Suarez G., Mendez F., et al. Persistence of HPV infection and risk of high-grade cervical intraepithelial neoplasia in a cohort of Colombian women. *Br J Cancer*. 2009;100(7):1184–1190.

Ola Germaniuk. 2016. *MTT Assay*. (Online), (<http://groups.molbiosci.northwestern.edu/morimoto/research/Protocols/II.%20Eukaryotes/E.%20Cell%20Growth/Death/2.%20MTT.pdf>), diakses 20 November 2016).

Parkin DM., Bray F.. Chapter 2: the burden of HPV-related cancers. *Vaccine*. 2006;24(suppl 3):S3/11–25.

Radaeli A., et al. 2010. Fowlpox virus recombinants expressing HPV-16 E6 and E7 oncogenes for the therapy of cervical carcinoma elicit humoral and cell-mediated responses in rabbits. *J of Translational Med* (8) :40.

Rodríguez AC., Schiffman M., Herrero R., et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. *J Natl Cancer Inst*. 2008;100(7):513–517.

Rodriguez AC., Schiffman M., Herrero R., et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. *J Natl Cancer Inst*. 2010;102(5):315–324.

Roman, Ann., et al. 2013. *The Papillomavirus E7 Proteins*. *Virology*(445) : 138-168.

Sasieni P., Castanon A., Cuzick J.. Screening and adenocarcinoma of the cervix. *Int J Cancer*. 2009;125(3):525–529.

Schiffman M., Clifford G., Buonaguro FM.. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. *Infect Agent Cancer*. 2009;4:8.

Schlecht NF., Kulaga S., Robitaille J., et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. *JAMA*. 2001;286(24):3106–3114.

Terry LR., Richard AM., Andrew LN., Sarah D., Hélène AB., Tracy JW., Lisa M.. 2016. *Cell Viability Assays*, (Online), (<https://www.ncbi.nlm.nih.gov/books/NBK144065/>, diakses 20 November 2016).

Trottier H., Mahmud SM., Lindsay L., et al. Persistence of an incident human papillomavirus infection and timing of cervical lesions in previously unexposed young women. *Cancer Epidemiol Biomarkers Prev*. 2009;18(3):854–862.

Wentzensen N., Vinokurova S., Von Knebel Doeberitz M.. Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. *Cancer Res*. 2004;64(11):3878–3884.

World Health Organization. 2014. *Prevention and Control for Cervical Cancer*, (Online), (<http://www.who.int/reproductivehealth/topics/cancers/hpv-vaccination/en/>, diakses 20 Oktober 2015).

Zur Hausen H.. Papillomaviruses and cancer: from basic studies to clinical application. *Nat Rev Cancer*. 2002;2(5):342–350.